Kenvue (NYSE:KVUE) receives a Neutral rating from Citigroup

Kenvue (NYSE:KVUE – Get Free Report)Citigroup equity analysts maintained a “neutral” rating in a research note issued to investors on Tuesday, according to Benzinga. They currently have a price target of $21.00 on the stock. Citigroup’s price target suggests a potential upside of 8.53% from the previous close.

A number of other brokerages also commented on KVUE. The Goldman Sachs Group began covering Kenvue in a research report on Friday, March 1st. They issued a “neutral” rating for the company and a target price of $20.00. Sanford C. Bernstein initiated coverage of Kenvue in a report on Thursday, April 11. They set an “underperform” rating on the company’s stock and a $18.00 price target. Royal Bank of Canada lowered their target price on Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a report on Friday, February 9th. JPMorgan Chase & Co. lowered their target price on shares of Kenvue from $25.00 to $24.00 and set an “overperform” rating on the stock in a report on Friday, February 9th. Finally, William Blair initiated coverage of Kenvue in a report on Wednesday, April 3. They have assigned a “market perform” rating for the stock. One analyst rated the company with a sell rating, eight with a hold rating, and seven with a buy rating. According to MarketBeat data, the stock’s average rating is currently “Hold” and the consensus price target is $24.00.

Check out our latest stock report on KVUE

Kenvue price performance

KVUE stock opened at $19.35 on Tuesday. The stock has a 50-day moving average price of $19.97 and a 200-day moving average price of $20.21. The company has a quick ratio of 0.68, a current ratio of 0.99 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $37.05 billion and a price-to-earnings ratio of 24.81. Kenvue has a 12-month low of $17.82 and a 12-month high of $26.74.

Kenvue (NYSE:KVUE – Get Free Report) last released its quarterly data on Tuesday, May 7th. The company observed EPS of $0.28 for the quarter, $0.03 above analyst consensus estimates of $0.25. The company had revenue of $2.89 billion for the quarter, compared to analyst estimates of $3.79 billion. Kenvue had a return on equity of 21.06% and a net margin of 9.63%. Kenvue’s revenue declined 24.9% year-over-year. Analysts expect Kenvue to report 1.15 EPS for the current year.

Institutional investors criticize Kenvue

Institutional investors have been buying and selling shares of the company recently. Clearstead Advisors LLC bought a new stake in shares of Kenvue during the 3rd quarter worth approximately $25,000. Manchester Capital Management LLC increased its holdings in Kenvue by 80.8% during the first quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock valued at $25,000 after acquiring an additional 530 shares in the last quarter. Planned Solutions Inc. purchased a new stake in shares of Kenvue during the fourth quarter worth approximately $27,000. Pacific Capital Wealth Advisors Inc. purchased a new stake in shares of Kenvue during the fourth quarter worth approximately $28,000. Finally, Mather Group LLC. purchased new shares of Kenvue during the first quarter worth approximately $28,000. Institutional investors hold 97.64% of the company’s shares.

Kenvue company profile

(Get the free report)

Kenvue Inc operates as a global consumer health company. The company operates in three segments: Self Care, Skin Health and Beauty and Essential Health. The Self Care segment offers cough, cold and allergy products, pain relievers, digestive aids, smoking cessation, eye care and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee’s, ORSLTM, Rhinocort, Calpol and Zyrtec brands.

Kenvue price performance

Institutional investors criticize Kenvue

Kenvue company profile

Further reading